These findings establish REP-1 as a key regulator of retinal metabolic homeostasis and suggest that targeting glucose-lipid metabolic rewiring may represent a novel therapeutic strategy for CHM and related retinal dystrophies. The gene discussed is CHM; the disease is inherited retinal dystrophy.